anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compositions suitable for topical use to treat ectoparasite infestations are described. The compositions are suitable for use on the hair of humans or animals, without the need for pharmaceuticals or medicaments. The compositions are essentially nonaqueous and non-Newtonian, such that the compositions can be controllably delivered either manually or through use of a dispensing means. One such exemplary dispenser/applicator is described. Although the compositions are otherwise substantially free of water, they exhibit good risibility characteristics and pseudoplastic rheology. Methods for the use of the nonaqueous compositions and kits containing the compositions are also presented.
Systems and methods for determining whether a patient should receive intensive therapy for a respiratory disease, such as a biologic prescription. Collecting usage data of a respiratory medicament device delivering a controlled respiratory medicament or an emergency respiratory medicament to the patient. The usage data is transmitted to the storage device. Storing the usage data in the storage device. Based on the usage data, the system determines whether the patient exceeded a first threshold level of compliance in use of the respiratory medicament device. Based on the usage data, the system determines whether the patient has emergency respiratory medication usage that exceeds a second threshold level. If the patient exceeds the first threshold and the second threshold, a notification is provided suggesting an intensive therapy.
Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
OBJECTIVE: To demonstrate a high-yield molecular diagnostic workflow for lateralized overgrowth (LO), a congenital condition with abnormal enlargement of body parts, and to classify it by molecular genetics.
STUDY DESIGN: We categorized 186 retrospective cases of LO diagnosed between 2003 and 2023 into suspected Beckwith-Wiedemann spectrum, PIK3CA-related overgrowth spectrum (PROS), vascular overgrowth, or isolated LO, based on initial clinical assessments, to determine the appropriate first-tier molecular tests and tissue for analysis. Patients underwent testing for 11p15 epigenetic abnormalities or somatic variants in genes related to PI3K/AKT/mTOR, vascular proliferation, and RAS-MAPK cascades using blood or skin DNA. For cases with negative initial tests, a sequential cascade molecular approach was employed to improve diagnostic yield.
RESULTS: This approach led to a molecular diagnosis in 54% of cases, 89% of cases consistent with initial clinical suspicions, and 11% reclassified. Beckwith-Wiedemann spectrum was the most common cause, with 43% of cases exhibiting 11p15 abnormalities. PIK3CA-related overgrowth spectrum had the highest confirmation rate, with 74% of clinically diagnosed patients showing a PIK3CA variant. Vascular overgrowth demonstrated significant clinical overlap with other syndromes. A molecular diagnosis of isolated LO proved challenging, with only 21% of cases classifiable into a specific condition.
CONCLUSIONS: LO is underdiagnosed from a molecular viewpoint and to date has had no diagnostic guidelines, which is crucial for addressing potential cancer predisposition, enabling precision medicine treatments, and guiding management. This study sheds light on the molecular etiology of LO, highlighting the importance of a tailored diagnostic approach and of selecting appropriate testing to achieve the highest diagnostic yield.
PURPOSE:To beautifully remove hair in a short time without unpleasant smell and irritation, by applying a hair removing agent containing a high polymer solution having film-forming properties and hair removing chemical, drying the coat, applying a pressure-sensitive adhesive film to the surface of the formed film and peeling the pressure-sensitive adhesive film. CONSTITUTION:A hair removing agent containing an aqueous solution of a high polymer, e.g. PVA, PVP, CMC, etc., or emulsion, e.g. natural rubber latex, polyvinyl acetate, etc., having film-forming properties and hair removing chemical is applied to a part for removing the hair and dried to form a film. A pressure-sensitive adhesive film is then applied to the surface of the dried film, which is, together with the pressure-sensitive adhesive film, peeled to remove the hair. Body hair in which the hair root part is weakened by the hair removing chemical is beautifully removed. Since the film is surely transferred and adhered to the surface of the pressure-sensitive adhesive layer of the film, no residual material of the film is left in the part for removing the hair.
The present invention relates to an attenuated African Swine Fever (ASF) virus, wherein : ? genes MGF 360-12L, 360-13L, 360-14L, 505-2R, 505-3R are deleted or are interrupted or mutated such that the genes are not transcribed and/or translated, ? ORF of ASFV_G_ACD_00520 is deleted or is interrupted or mutated such that it is not transcribed and/or translated, and ? genes MGF 505-1 R et 505-4R are truncated, compared to the genome of the corresponding unattenuated virus. The present invention also refers to a vaccine comprising the attenuated ASF virus, and its use in preventing African Swine Fever in a subject. The present invention also relates to an in-vitro method for obtaining the attenuated ASF virus, which comprises at least one step of thermal- attenuation of a virulent ASFV virus strain selected among Georgia 2007/1, Pig/HLJ/2018, a strain of ASF virus of genotype II or a genetically close ASF virus strain, and amplification by inoculation of Specific-Pathogen- Free pigs and selecting said attenuated ASF virus. The present invention refers to an in vitro method for the differential detection of the attenuated ASF virus and of the corresponding non- attenuated ASF virus as well.
CONTEXT: Loose tumor cells and tumor cell clusters can be recognized in the lumen of intratumoral pulmonary arteries of resected non-small cell lung cancer specimens. It is unclear whether these should be considered tumor-emboli, and as such could predict a worsened prognosis.
OBJECTIVE: To investigate the nature and prognostic impact of pulmonary artery intraluminal tumor cells.
DESIGN: This multicenter study involved an exploratory pilot study and a validation study from 3 institutions. For the exploratory pilot study, a retrospective pulmonary resection cohort of primary adenocarcinomas, diagnosed between November 2007 and November 2010, were scored for the presence of tumor cells, as well as potentially other cells in the intravascular spaces, using hematoxylin-eosin and cytokeratin 7 (CK7) stains. In the validation part, 2 retrospective cohorts of resected pulmonary adenocarcinomas, between January 2011 and December 2016, were included. Recurrence-free survival (RFS) and overall survival (OS) data were collected.
RESULTS: In the pilot study, CK7+ intravascular cells, mainly tumor cells, were present in 23 of 33 patients (69.7%). The 5-year OS for patients with intravascular tumor cells was 61%, compared with 40% for patients without intravascular tumor cells (P = .19). In the validation study, CK7+ intravascular tumor cells were present in 41 of 70 patients (58.6%). The 5-year RFS for patients with intravascular tumor cells was 80.0%, compared with 80.6% in patients without intravascular tumor cells (P = .52). The 5-year OS rates were, respectively, 82.8% and 71.6% (P = .16).
CONCLUSIONS: Loose tumor cells in pulmonary arterial lumina were found in most non-small cell lung cancer resection specimens and were not associated with a worse RFS or OS. Therefore, most probably they represent an artifact.
The present invention relates to composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) fused to at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules. Further, the invention relates to a composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) or with at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules, which is fused to at least one viral export element. The present invention also relates to said compositions for use in therapy. In particular, the present invention relates to said compositions for use in a method of preventing or treating a viral or a bacterial disease in a subject. The present invention further relates to nucleic acid molecules comprising a nucleotide sequence encoding said Cas13 protein and/or said gRNA of said compositions, vectors comprising said nucleic acid molecules and host cells comprising the vectors or the nucleic acid molecules. Further, the present invention relates to kits comprising the compositions. The invention also comprises methods of producing said compositions of the present invention.
Relaxation is a low-cost treatment for managing pain with little or no side effects. The proposed study will use a novel biofeedback procedure to try to enhance the ability of relaxation to engage pain inhibition. Specifically, a biofeedback system will be used to provide training in conditioned pain regulation. The biofeedback system will monitor the trainee's level of sympathetic arousal and use it to control the intensity of painful stimulations delivered to the trainee during biofeedback. So when the trainee successfully relaxes (and reduced arousal), the intensity is lowered and produces pain relief. Efficacy of the training will be tested in a randomized controlled trial in which healthy, pain-free trainees are assigned to receive 3 training sessions or 3 sessions of a control procedure (2 other procedures will serve as controls; 3 groups total). The aim will be to assess whether the training results in inhibition of experimental pain and the nociceptive flexion reflex (NFR, a physiological marker of spinal pain signaling) to determine whether brain-to-spinal cord inhibitory circuits are engaged.
Newborns in this group were started to camera recording 2 minutes before the procedure and routine OGT placement was performed. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.After OGT insertion, a light touch was provided if necessary to ensure routine comfort of the baby for ethical reasons.
Peptides have been identified that bind with high affinity to hair, skin, and nails. Peptide-based hair conditioners, hair colorants, skin conditioners, skin colorants, and nail colorants based are described. The peptide-based hair conditioners and hair colorants consist of a hair-binding peptide coupled to a hair conditioning agent or a coloring agent, respectively. The peptide-based skin conditioners and skin colorants consist of a skin-binding peptide coupled to a skin conditioning agent or a colorant, respectively. The peptide-based nail colorants consist of a nail-binding peptide coupled to a coloring agent. In all these compositions, the peptide may be directly coupled to the active agent or the coupling may be via a spacer. Personal care compositions containing these peptide-based conditioners and colorants are also described.
The presente invention relates to a stable, preferably aqueous, food cleaning composition, preferably for use on produce and/or food contact surfaces. The composition typically comprises from about 0.1 % to about 20 %, by weight of the composition, of solubilized, water-soluble, uncomplexed cyclodextrin and an effective amount of at least one ingredient to improve the performance of the composition selected from the group consisting of: (1) cyclodextrin compatible surfactant; (2) cyclodextrin compatible antimicrobial active; and (3) mixtures thereof. Optional hydrophilic perfume improves acceptance. Optionally, the composition can contain low molecular weight polyols; metallic salts to help control odor; etc. The composition is preferably essentially free of any material that is not food compatible. The composition is preferably applied as small particle size droplets, especially from spray containers. The surfactant/antibacterial active combination, provides improved antimicrobial activity.
This invention relates to a method and a class of pharmaceutical agents for suppressing vomiting, nausea, and other emetic symptoms. The method involves administering to a susceptible mammal a glutamate (EAA) receptor antagonist at an anti-emetically effective dose which does not cause undesirable side effects. Preferred EAA antagonists include those that do not readily cross blood-brain barriers (BBB). One suitable formulation comprises a broad-spectrum antagonist such as kynurenic acid or 7-chlorokynurenate. Other formulations include EAA antagonists that preferentially block NMDA receptors (such as D-AP5) or non-NMDA receptors (such as CNQX), or mixtures thereof that can block both classes of EAA receptors. In lab tests, the agents of this invention were shown to reduce or entirely block the effects of several emetic agents, including cisplatin. Treated animals did not vomit or exhibit lethargy or malaise and did not display any adverse side effects, while control animals consistently displayed lethargy, malaise, and vomiting.
PCT No. PCT/CA90/00062 Sec. 371 Date Aug. 21, 1991 Sec. 102(e) Date Aug. 21, 1991 PCT Filed Feb. 23, 1990 PCT Pub. No. WO90/10230 PCT Pub. Date Sep. 7, 1990A polypeptide having immunological activity for use as a diagnostic reagent for the HIV. The polypeptide comprises a substantial portion of each of more than one of the constituent proteins coded for by the HIV-pol gene, namely the amino acid sequences of the reverse transcriptase, RNase H and integrase enzymes coded for by the HIV-pol gene and the amino acid sequences of part of the protease enzyme coded for by the HIV-pol gene, but omitting the active site responsible for proteolytic activity.
PURPOSE:To purify riboflavin in high purity to enable sufficient control of color tone without using oxidizing agent by dissolving crude riboflavin in a mineral acid and precipitating in a mixture of an organic solvent and water. CONSTITUTION:Crude riboflavin is dissolved in a mineral acid (e.g. hydrochloric acid and sulfuric acid) preferably diluted with water and the solution is optionally treated with active carbon or filter aid, etc., and filtered. Riboflavin is precipitated from the solution with an organic solvent-water system (e.g. butanol- water or dioxane-water) heated at 40-100 deg.C and the mixture is cooled to 30 deg.C and filtered to obtain purified riboflavin. The amount of the mineral acid solution is 1-5 pts. based on 1 pt. of riboflavin and the mixing ratio of the organic solvent to water is selected to give a mixed liquid containing 5-95vol.% of the organic solvent. Riboflavin is useful as a growth promotion factor, vitamin B2 necessary for preventing angular stomatitis and inflammation of eye or a yellow colorant.
Extracts obtained from or obtainable from Rubus idaeus (red raspberry) for use in treating or preventing inflammation are disclosed. The inflammation may be arthritis. The extract may reduce joint degeneration and swelling. The leaves and stems may be ground and extracted in an aqueous ethanol solvent. The extract may be formulated into a pharmaceutical composition suitable for oral, rectal, nasal, pulmonary, buccal, sublingual, transdermal, intracisternal, intraperitoneal or parenteral administration, or formulated into a food or drink composition or product. The composition may be suitable for treating animals and/or humans.
Participants receive 1 dose of Scopolamine 0.2 mg, 1 dose of Scopolamine 0.4 mg, and 1 dose of placebo saline delivered via the Creare LLC intranasal nebulizer. These dosages are all 1 week apart and the order is randomized.
The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
Background Although there has been growth in online STI testing services, more attention is needed to understand how to facilitate effective treatment pathways for users. This study investigated where young people want to be treated for gonorrhoea and syphilis if they test positive using an online service. Methods We conducted an online survey of Australians aged 16-29years that included multiple choice and free-text questions about their preferred location for receiving injectable antibiotics. Multivariable multinomial logistic regression examined associations between respondent characteristics and service preferences. Content analysis was used to code free-text responses. Results Among 905 survey respondents, 777 (85.9%) answered questions on treatment preferences. Respondents most commonly preferred injectable antibiotics provided by a sexual health clinic (294; 37.8%) or a nurse in a pharmacy (208; 26.8%). Gender/sexually diverse respondents were more likely to select sexual health clinics over general practice (MSM RRR 2.5, 95% CI 1.1-5.7; WSW RRR 2.6, 95% CI 1.1-5.7; trans/non-binary RRR 2.5; 95% CI 1.0-6.0). Older respondents (aged 25-29years) were more likely to choose all alternatives over general practice, with the reverse found for those who had previously tested. From open-text answers, pharmacies were valued for their convenience, and sexual health clinics for providing non-judgemental, free services by specialists. Conclusions Differences in treatment preferences by certain groups of young people suggest that different service offerings may influence treatment-seeking outcomes from online STI testing services.
For patients randomized to the CC arm, in addition to the provider being alerted to the positive Mental Health and Substance Use Disorder screener, the patient will also be assigned to a peer case manager (P-CM). The P-CM will provide longitudinal care for the patient as part of their care management case load. The collaborative care support team will include the P-CM, a consultant addiction psychiatrist and the patient's HIV provider who will implement a stepped care program consisting of: 1) an initial assessment, determination of and implementation of an individualized care plan to provide; 2) psychosocial and medication adherence support; 3) evidence-based brief intervention incorporating motivational interviewing informed strategies; 4) measurement-based care for Mental Health and Substance Use Disorder provided directly by the HIV primary care provider or in collaboration with specialty Mental Health and Substance Use Disorder services.
In the experimental group, hand holding will be done by the researcher, and intramuscular injection will be done by the clinical nurse. All intramuscular injections will be performed by a single nurse and the ventrogluteal region will be used as the injection site. Patients will first fill out the Voluntary Information and Consent Form, and then the Descriptive Characteristics Form and State Anxiety Scale. After the injection site is evaluated, the researcher will hold the patient's hand, the nurse will enter the tissue at a 90-degree angle and administer the drug slowly (1 ml/10 seconds). After removing the needle from the tissue, the nurse will apply pressure with dry cotton, and then the researcher will stop holding the patient's hand. After the procedure, the Numerical Pain Scale and State Anxiety Scale will be filled in within 1 minute.
Double-blind, multi-center, placebo-controlled, 2-period crossover study which assessed the efficacy and safety of gabapentin enacarbil (GEn; GSK1838262; XP13512) extended release tablets in adults with Restless Legs Syndrome (RLS)-associated sleep disturbance. One hundred thirty-six (136) adult subjects with RLS-associated sleep disturbance and periodic limb movements (PLM) were randomized from 23 centers in the United States. Subjects who met all eligibility criteria were randomized to receive a treatment sequence of GEn:placebo or placebo:GEn. Investigational product was taken with food at approximately 5pm. Investigational product was dosed as 600mg/day x3 days followed by 1200mg/day x25 days for each 4-week treatment period. There was a 1-week taper at 600mg after each treatment period followed by a 1-week washout between treatments. Polysomnography (PSG) was used to objectively evaluate changes in sleep and PLMs.
INTRODUCTION: Rasmussen's encephalitis (RE) is a rare, predominantly pediatric epilepsy disorder of unknown etiology. It classically affects one of the cerebral hemispheres and histologically shows cortical chronic inflammation, gliosis, and neuronal loss. The etiopathogenesis of RE remains unknown, with genetic, infectious, and autoimmune factors all speculated to play a role. Although the histologic findings in RE are well described, few studies have investigated a large cohort of cases looking for the coexistence of RE with focal cortical dysplasia (FCD).
DESIGN: The study is a retrospective review of RE patients who underwent surgical resection of brain tissue between 1979 and 2021. Relevant patient history was retrieved, and available histologic slides were reviewed. The histologic severity of RE was described according to the Pardo criteria. In cases where FCD was present, the observed patterns of FCD (namely Ia, Ib, IIa, IIb, etc.) were described using the International League Against Epilepsy (ILAE) classification.
RESULTS: Thirty-eight resection specimens from 31 patients formed the study cohort. Seventeen patients (54.8 %) were male; average age at surgery was 8 years (range: 2-28 years). Twenty-seven resection specimens (71.1 %) from 23 patients (74 %) showed evidence of coexistent FCD. Most cases with FCD resembled the ILAE type Ib (n = 23) pattern. Cases of RE that did not show FCD were either Pardo stage 1 (n = 5) or 4 (n = 6), with all Pardo stage 2 and 3 cases demonstrating FCD.
CONCLUSIONS: FCD was found in most patients with RE (74 %). The most observed pattern of FCD was ILAE Ib.
This group will include 40 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist. After 6 weeks, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.